← Back to Search

Vaccine

Menactra Vaccine for Meningitis Prevention (PLAT Trial)

Phase 4
Waitlist Available
Led By Lindsey Baden, MD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet the standard requirements to donate platelets
Have had at least one plateletpheresis in the prior 365 days (including the day of enrollment)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up months 1 and 6.
Awards & highlights

PLAT Trial Summary

This trial will test how well a new meningitis vaccine works in healthy people who often donate platelets.

Who is the study for?
This trial is for adults over 18 who regularly donate platelets and meet the standard criteria for donation. They must have donated platelets at least once in the past year but not at multiple centers. People with severe allergies to meningococcal vaccines or a history of Guillain-Barré syndrome cannot participate.Check my eligibility
What is being tested?
The study is testing the immune response to Menactra, a quadrivalent conjugate meningococcal vaccine, in frequent platelet donors to see how well it works in this specific group.See study design
What are the potential side effects?
Possible side effects of Menactra include soreness at injection site, fatigue, headache, muscle pain, and rare allergic reactions.

PLAT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I meet the health criteria to donate platelets.
Select...
I have undergone plateletpheresis within the last year.

PLAT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~months 1 and 6.
This trial's timeline: 3 weeks for screening, Varies for treatment, and months 1 and 6. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Vaccines
Secondary outcome measures
Seroprotection

PLAT Trial Design

3Treatment groups
Active Control
Group I: Low number plateletpheresis donationsActive Control1 Intervention
Participants that have had 1-2 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
Group II: Medium number plateletpheresis donationsActive Control1 Intervention
Participants that have had 3-19 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.
Group III: High number plateletpheresis donationsActive Control1 Intervention
Participants that have had 20-24 plateletpheresis donations in the last 365 days. Menactra will be administered as a 0.5 mL dose.

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,615 Previous Clinical Trials
11,470,728 Total Patients Enrolled
Lindsey Baden, MDPrincipal InvestigatorBrigham and Women's Hospital
7 Previous Clinical Trials
863 Total Patients Enrolled

Media Library

Menactra (Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT04224311 — Phase 4
Preventive Immunization Clinical Trial 2023: Menactra Highlights & Side Effects. Trial Name: NCT04224311 — Phase 4
Menactra (Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04224311 — Phase 4
Preventive Immunization Research Study Groups: Low number plateletpheresis donations, Medium number plateletpheresis donations, High number plateletpheresis donations

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What previous research has been done into the effects of high volume plateletpheresis donations?

"Presently, there are two research initiatives for High number plateletpheresis donations. Neither of these studies is at the Phase 3 stage yet. Primarily based in Boston, Massachusetts, both trials are being conducted across 2 different locations."

Answered by AI

Is High number plateletpheresis donations a risk-free method of donation for individuals?

"Power's internal assessment suggests that high number plateletpheresis donations are safe enough to warrant a score of 3. This is due to the fact this intervention has already been approved and there have been multiple rounds of data collection confirming its safety."

Answered by AI

Does this experiment presently have any openings for participants?

"Clinicaltrials.gov reports that this particular trial, which was initially posted on March 12th 2020 and last modified on November 13th 2022, is no longer enrolling patients at this time; however, there are 34 other studies actively searching for candidates right now."

Answered by AI

What is the current enrollment rate of this medical research?

"Unfotunately, this trial is not presently recruiting. The study was initiated on March 12th 2020 and the information has been revised on November 13 2022. If you are still interested in taking part in a clinical trial, there are 32 actively searching for patients that can benefit from preventive immunization; meningitis or high number plateletpheresis donations."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors
Lindsey R. Baden, MD 2020. "Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04224311.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top